Sungen: Bispecific Antibody, Bispecific Antibody Companies

Sungen Biomedical was founded in 2019 which is an innovative antibody drug research and development enterprise incubated by Hotgen Biotech (SH688068), a listed company on the Shanghai Stock Exchange. The co-founder of Sungen Biomedical is Professor Zhiwei Sun, Vice Chairman of China Monoclonal Antibody Industry Committee.

Learn More About Us 

What Does Sungen Achieve?

Sungen Biomedical, founded in 2019 and incubated by Hotgen Biotech, specializes in innovative antibody drugs and large molecule biopharmaceuticals. With a robust R&D pipelines, cutting-edge technology platforms, and strategic collaborations, we are committed to advancing medical science and improving patient outcomes globally.

Explore Sungen Research Innovation 

Technological Platforms

Innovation Achievements

Scientific Frontiers

Sungen News

View all articles 

Apr

What Are the Types of Bispecific Antibodies?

What is a Bispecific Antibody?Bispecific antibodies are a class of antibody molecules that can simultaneously recognize and bind to two different antigens or antigen epitopes. Compared to traditional ...

Read article >

Apr

How AI is Transforming the Pharmaceutical Industry?

Traditional drug discovery has long been a costly and uncertain process, requiring around $2.6 billion and over ten years to bring a drug to market, with a success rate of less than 10%. However, arti...

Read article >

Apr

How AI Accelerates Antibody Discovery

A groundbreaking study by Canada's National Research Council highlights the impressive capabilities of AI-enhanced molecular docking, which outperforms traditional methods in predicting the three-...

Read article >